NEW DELHI -- Biocon Biologics, a subsidiary of Indian biotech giant Biocon, has secured board approval for an investment of $150 million from U.S.-based investment bank Goldman Sachs.
As part of the agreement, Goldman Sachs will be issued convertible debentures at a post-money equity valuation of $3.94 billion, the parent said in a statement.
